. 2020 Oct 8;111(12):4558–4566. doi: 10.1111/cas.14661

TABLE 1.

Overview of the datasets used in this study

Dataset	Source	Assay	Sample type	Number of samples
Discovery set (N = 440)
	TCGA CRC	Infinium 450K	Tissue	Normal = 45, CRC = 395
Test set (N = 938)
Test set A	GSE42752	Infinium 450K	Tissue	Normal = 41, CRC = 22
	GSE48684 ^a	Infinium 450K	Tissue	Normal = 41, CRC = 64
	GSE68060 ^a	Infinium 450K	Tissue	Normal = 36, CRC = 82
	GSE77718	Infinium 450K	Tissue	Normal = 96, CRC = 96
	GSE77954	Infinium 450K	Tissue	Normal = 11, CRC = 13
	GSE101764	Infinium 450K	Tissue	Normal = 149, CRC = 112
	GSE107352	Infinium 450K	Tissue	Normal = 21, CRC = 30
Test set B	GSE48684 ^a	Infinium 450K	Tissue	Normal = 41, Adenoma = 42
	GSE77954 ^a	Infinium 450K	Tissue	Normal = 11, Adenoma = 12
	GSE129364	Infinium 450K	Tissue	Normal = 3, Adenoma = 59
Test set C	GSE122126	Infinium EPIC	cfDNA	Normal = 4, CRC = 4
Validation set (N = 374)
	Inhouse study	Targeted bisulfite sequencing	Tissue	Normal = 23, Polyp = 10, Adenoma = 8, CRC = 275
	Inhouse study	Targeted bisulfite sequencing	WBC	Normal = 29, CRC = 29

Abbreviations: cfDNA, cell‐free DNA; CRC, colorectal cancer; TCGA, The Cancer Genome Atlas; WBC, white blood cell.

^{^a}

Normal tissues from GSE48684 and GSE77954 were used in both test set A and test set B.